Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive
Clinical trial NCT04249739 · UNKNOWN
Trial details
- NCT number
- NCT04249739
- Sponsor
- Samsung Medical Center
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-09-29
- Primary completion
- 2024-02-06
- Enrollment
- 93
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.